Table 2 Association of cuproptosis related genes and cancers
Ref | database | cancer | risk factor | protective factor | microenviroment condition | Clinical value |
|---|---|---|---|---|---|---|
[129] | TCGA | LUAD | DLAT, DLD, DLST and PDHA1 | DBT and LIPT1 | high risk related to immune cell infiltration reduction and less activity in HLA, type I and II IFN response | high risk led to worse OS together with higher mortality and more advanced T and N stage |
[130] | TCGA, GSE68465 | LUAD | DLAT | CDKN2A, PDHA1and MTF1 | high risk led to less immune cell infiltration | higher risk score corelated with worse OS, more advanced pathological stage, positive lymph nodes and more severe tumor status |
[131] | TCGA, GTEx, NODE, ICGC | HCC | ATP7A, LIPT1, DLAT, MTF1, GLS, and CDKN2A | none | high risk related to immunosuppressive microenviroment, immune cell infiltration reduction and macrophage polarization inhibition | high risk score correlated with worse survival |
[132] | TCGA | liver cancer | DLAT | ATP7A, GLS | higher risk score correlated with worse immune status and higher expression of immune check point genes | higher risk correlated with worse OS and clinicopathological features |
[133] | TCGA, GSE76427 | HCC | MANEA, PGM2, PTTG1 | CGNL1, ALAS1 | higher risk score correlated with actived CD4 + T | higher risk score correlated with higher mortality and worse OS |
[134] | TCGA, ICGC, TISCHGSE64041, GSE14520/GPL3921, GSE76427, GSE104580, GSE109211, and GSE25097 | HCC | CAT, SLC27A, EHHADH, ALDH5A1 | none | higher risk score correlated with protumor immune infiltration and higher expression of immun check point genes | higher risk score correlated with worse OS, PFS and clinicopathological features |
[135] | TCGA, GSE76427 | HCC | PBK, MMP1, GNAZ, GPC1 | AKR1D1 | higher risk score correlated with protumor immune infiltration | higher risk score correlated with worse OS |
[136] | TCGA, GSE14520 | HCC | KIF2C, PTTG1, CENPM, CDC20, SFN | CYP2C9, CFHR3 | higher risk score correlated with less immune cell infiltration and higher expression of immun check point genes | higher risk score correlated with worse OS |
[137] | TCGA, GTEx | CC | ATP7A, DLAT, GCSH | DBT, FDX1, LIPT1, PDHA1 | higher risk score correlated with less immune cell infiltration | higher risk score correlated with worse OS and more advanced clinical stage |
[138] | TCGA | USEC | CDKN2A, GLS, and LIPT1 | none | not mentioned | higher risk correlated with worse OS, PFS and DFS |
[139] | TCGA, GSE22138 | UVM | LIPT1, DLD, PDHA1, CDKN2A | LIAS, PDHB, MTF1, GLS | no significant difference in the total immune cell infiltration | higher risk correlated with more advanced clinical stage |
[140] | TCGA, GTEx, CGGA | LGG | C21orf62, DRAXIN, ITPRID2, MAP3K1, and MOXD1 | none | higher risk score correlated with higher TME scores and lower CSC index, also with higher expression of immun check point genes | higher risk correlated with worse OS and more cases of death |
[141] | TCGA, GTEx, CGGA311, CGGA668, GSE108474, GSE13041, GSE16011, GSE43289, GSE43378, GSE4412, GSE4412, GSE68838, and GSE83300 | giloma | H19, CYTOR, IGFBP2 and CHI3L1 | KLRC2 and C5orf38 | higher risk score correlated with higher immune infiltration and less immune function | higher risk correlated with more advanced clinical stage |
[142] | TCGA, CGG, AGSE84465 | giloma | SLC31A1, NFE2L2, MT1M, MT1H, MAP1LC3A, FDX1, COX19, ARF1, AOC1 | LIAS, CYP1A1, ATP7B | higher risk score correlated with higher immune infiltration and less immune function | higher risk correlated with more advanced clinical stage |
[143] | TCGA, CGGA | giloma | FDX1, DLD, MTF1 | DLAT, CDKN2A | higher risk score correlated with higher protumor immune infiltration | higher risk score correlated with worse OS |
[144] | TCGA, GSE17538, GSE29623, GSE39582 | CRC | CDKN2A, GLS | DLAT | higher risk score correlated with less immune cell infiltration and more stormal cells | higher risk correlated with more advanced clinical stage and worse OS |
[145] | TCGA, GSE61304 | BC | PGK1, PRDX1, MAL2, and SURF4 | RPL14, PSME1 | higher risk score correlated with higher immune activation | higher risk correlated with worse OS and PFS |
[146] | TCGA, GSE58812, GSE135565 and GSE65194 | TNBC | ATP7A | LIPT1 | higher risk score correlated with less immune cell infiltration and lower TME score | higher risk correlated with worse OS and more advanced clinical stage |
[147] | TCGA, GSE168410, GSE20685 and GSE20711 | BC | DLAT, SNX3, TTC3, PHF20, RTN4, SURF4, SDC1, KDELR2, BAMBI, ANXA5, MARVELD | RBP1, TPT1, MDK, RPLP1, ETV6 | higher risk score correlated with more active immune function and higher immune check point genes expression | higher risk correlated with worse prognosis |
[148] | TCGA, GSE40435 and GSE53757 | KIRC | CDKN2A | FDX1, DLAT | not mentioned | higher risk correlated with worse OS and PFS |
[149] | TCGA, E-MTAB-1980, ICGC, GSE64052 | KIRC | FDX1, CDC42BPG, C11orf52, GNG7, PAQR5, ENAM, WDR72, SDR42E1, BSPRY and KDF1 | TMEM214, CCM2 and P3H4 | higher risk score correlated with higher expression of immune check point genes | higher risk correlated with worse OS and DFS |
[150] | TCGA, GSE12606, GSE53000, and GSE53757 | KIRC | none | ENAM, WDR72, CLDN10, HMGCS2, CYFIP2, QRFPR | higher risk score correlated with more immune cells infiltration | higher risk correlated with worse clinicopathological features |
[151] | TCGA | HNSCC | PRKN, MT1E, CXCL8, COX11, COX5A, COX19, ACLY | CYP2D6, ABCB1, CCL5, LOXL1, CDKN2A, BCL2, DAPK2 | higher risk score correlated with less immune cell infiltration and immune function | higher risk correlated with worse OS and clinicopathological features |
[152] | TCGA | HNSCC | not mentioned | not mentioned | higher risk score correlated with higher expression of immune check point genes, less immune function and lower TME score | higher risk correlated with worse OS, PFS, DFS and clinicopathological features |
[153] | TCGA, GSE41613 and GSE65858 | HNSCC | PRELID2, ANP32B, MRPL47, and CCDC59 | CDKN2A, WDR90, NLRX1 and KCNK6 | higher risk score correlated with higher expression of immune check point genes | higher risk correlated with worse OS |
[154] | TCGA, GSE41613 and GSE42743 | HNSCC | not mentioned | not mentioned | higher risk score correlated with higher expression of immune check point genes | higher risk correlated with worse OS and more advanced clinical stage |
[155] | TCGA | ESCA | SLC25A5, SLC23A2, PDHX, ATP7A, and COX7B | PHID2 | higher risk score correlated with more immune cells infiltration | higher risk correlated with worse prognosis |
[156] | TCGA, ICGC | PAAD | KRAS, TP53, BRCA1, BRCA2, DLAT | CDKN2A, SMAD4, LIAS, LIPT1, DLD, PDHA1, MTF1, GLS | higher risk score correlated with low TME scores and expression of immune check point genes | higher risk correlated with worse OS |
[157] | TCGA, GTEx | PAAD | DLAT | LIPT, LIAS | higher risk score correlated with more immune cells infiltration | higher risk correlated with worse OS |
[158] | TCGA, ICGC, GTEX, IMvigor210 | PAAD | DLAT, TIMMDC1, GSS | NDUFB2, LIAS, NDUFA8, ISCA2 | higher risk score correlated with more immune supression | higher risk correlated with less survival probablity |
[159] | TCGA, GSE30219, GSE31210 and GSE37745 | LUAD | LINC00205, LINC00592 and AL162632.3S | AC026355.2, LINC02848 and ZNF571AS1 | higher risk score correlated with greater potential for immune escape and suppressed immune function | higher risk score correlated with worse OS, PFS and higher mortality |
[160] | TCGA, GSE130740 | LUAD | AL031667.3, AL606489.1 and MIR31HG | AC008764.2, AL022323.1, ELN-AS1 and LINC00578 | higher risk score correlated with lower score of most pathways related to immune and less immune cells infiltration | higher risk correlated with worse OS |
[161] | TCGA | HCC | miR-767-5p, miR-5003-3p, miR-137-3p, miR-760, miR-548f-3p, miR-3171, miR-3189-3p, miR-3620-3p, miR-3911, miR-4652-3p, miR-504-3p, miR-892a, miR-548aq-5p | miR-67645p | higher risk score correlated with higher expression of immuno check point genes | higher risk correlated with worse OS |
[132] | TCGA | liver cancer | POLH-AS, AL117336.2, MKLN1-AS, AC005479.2, AL928654.1, AL031985.3 | none | higher risk score correlated with worse immune status and higher expression of immune check point genes | higher risk correlated with worse OS, more advanced clinical stage |
[162] | TCGA, GTEx | HCC | AC138904.1, DEPDC1-AS1, GIHCG, AC145343.1 | AC099329.2, DNMBP-AS1 | higher risk score correlated with actived CD4 + T and higher expression of immune check ponit genes | higher risk correlated with worse OS |
[163] | TCGA | PHC | MIR210HG, AC099850.3, AL031985.3, C012073.1, MKLN1-AS, KDM4A-AS1 and PLBD1-AS1 | none | risk score correlated with less immunce cell infiltration | higher risk correlated with worse OS |
[164] | TCGA, GTEx | CC | AL354733.3 and AC009902.2 | AL441992.1, LINC01305, AL354833.2, CNNM3-DT and SCAT2 | risk score correlated with less immunce cell infiltration and down regulation of immune functions and less Immune checkpoint gene expression | higher risk correlated with worse OS and PFS and worse clinicalpathological features |
[165] | TCGA, GSE16088 | OS | AL645608.6, AL591767.1 and UNC5B-AS1 | CARD8-AS1, AC098487.1 and AC005041.3 | higher risk score correlated with less immune infiltration and immune function | higher risk correlated with worse OS |
[166] | TARGET | OS | AL033384.2 | AL031775.1, AC110995.1 and LINC00565 | higher risk score correlated with higher infiltration of immunosuupressive cell and less immune effective cell infiltration and immune function | higher risk correlated with worse OS |
[167] | TCGA | SKCM | none | VIM-AS1, AC012443.2, MALINC1, AL354696.2 and HSD11B1-AS1 | higher risk score correlated with less immune infiltration, downregulation of immune function and immune check point gene expression | higher risk correlated with worse OS |
[168] | TCGA | CM | AC009495.1 | LINC01150, EBLN3P, MIR100HG, WAC − AS1, LINC00339 and USP30 − AS1 | higher risk score correlated with less immune infiltration and less immune check point genes expression | higher risk correlated with worse OS |
[169] | TCGA, GTEx, CGGA | LGG | CRNDE, FAM181A-AS1 | HAR1A | higher risk score correlated with higher immune cells infiltration, TME scores and immune check point genes expression | higher risk correlated with worse clinicalpathological features, lower survival rate and worse clinical outcone |
[170] | TCGA | CRC | AP003119.3, RNF216P1, AC156455.1, AL360270.1, AC139720.2, AC092614.1, LRP4-AS1, AP003555.1, AL513550.1 and AL512306.2 | AC073896.3, LINC00511, AC026979.4, AC103703.1, LRP1-AS | higher risk score correlated with supressed immune function | higher risk correlated with worse OS and PFS |
[171] | TCGA | CRC | AP001619.1, AC020917.2, AC002066.1, LINC01252, AC010789.2, LINC02542, AL356804.1 and ZFHX2-AS1 | AC008752.2 and AC012313.5 | higher risk score correlated with supressed immune function, less immune cell infiltration and less expression of immune check point genes | higher risk correlated with worse OS and clinical outcome |
[172] | TCGA | CRC | LINC00861, AC090517.2, AC01233.5, AL513550.1, AC026979.4, AC064836.3, PRKAR1BAS2, LINC02175, ZNF775AS1, AL161729.4 | AC073896.3 | higher risk score correlated with less iimmune cells infiltration | higher risk correlated with worse clinical outcome |
[173] | TCGA, GSE42743 | OSCC | C6orf99, AC010894.2, AC099850.4, RPL23AP7 | AC090587.2, AL513190.1, AC098484.2 | higher risk score correlated with lower TME score | higher risk correlated with worse prognosis and higher mortality rate |
[174] | TCGA | BC | AC079922.2, ZNF197-AS1, AC002398.1, AL451085.3, LINC02446 | GORAB-AS1, AL589765.4, AC005696.4, CYTOR, YTHDF3-AS1, AC008771.1 | higher risk score correlated with inactive immune function and less expression of immune check point genes | higher risk correlated with worse OS |
[175] | TCGA, E-MTAB-1980 | KIRC | FOXD2-AS1, NUP153-AS1, LINC02154 | SUCLG2-AS1, LINC00271 | higher risk score correlated with less iimmune cells infiltration and higher TME score | higher risk correlated with worse OS and DFS |
[176] | TCGA | KIRC | LINC01605, AGAP2-AS1, FOXD2-AS1, LINC02195 | none | higher risk score correlated with more immune check point genes expression | higher risk correlated with worse OS and clinicopathological features |
[177] | TCGA | KIRC | HHLA3, H110-AS1, PICSAR, SNHG15, LINC00471, LINC02154, MINCR | LINC02027, SNHG8, EIF1B-AS1 | higher risk score correlated with higher TME score and immune check point genes expression | higher risk correlated with worse OS |
[152] | TCGA | HNSCC | AL359397.1, AC098679.1, AC008014.1, C6orf99, LINC01106 | LINC00278, AC106820.3, AC007406.3, AC106820.5, AC022182.2, AP006621.4, TTTY14, AP006545.1, AC067930.3, DCST1 − AS1, AC022167.3, AC022098.1, AC020907.1 | higher risk correlaed with CD4 memory resting T cells infiltration | higher risk correlated with shorter survival |
[178] | TCGA | HNSCC | AL132800.1, AC 079,160.1, AL157888.1, SNHG16 | AC021148.2, AC090587.1, AC011462.4, GRHL3-AS1 | higher risk score correlated with low immune escape | higher risk correlated with worse OS and more advanced clinical stage |
[179] | TCGA | HNSCC | AC004943.2, TTN-AS1, AL132800.1, WDFY3-AS2 | AC090587.1, AL136419.3, AC012313.5, AC106820.5, AL162458.1, CDKN2A-DT | higher risk score correlated with lower TME score and more immune dysfunction | higher risk correlated with worse OS and clinicopathological features |
[180] | TCGA | STAD | LINC01094, AC022182.1, AC011747.1, LINC02476, AC090809.1, AC084781.2, SENCR | AC005014.2, AC010422.4 | higher risk score correlated with higher expression of immune check point genes | higher risk correlated with worse prognosis |
[181] | TCGA | STAD | LINC01150, SNAP25-AS1, HAGLR | LINC00571 | higher risk score correlated with higher immune function and expression of immune check point geens | higher risk correlated with worse OS and clinicopathological features |
[182] | TCGA | BLCA | AC080023.1 | AC010168.2, AC018653.3 | higher risk score correlated with higher immune functions and immune cells infiltration | higher risk correlated with worse OS and clinicopathological features |